Physician profile
Thomas D Sabin
NPI 1598877946
$792.63
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2020: $114.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $531.82 | 2019-2020 | |
| Allergan, INC. | $46.89 | 2019 | |
| Alexion Pharmaceuticals, INC. | $36.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $34.58 | 2019 | |
| Csl Behring | $23.04 | 2019 | |
| Ucb, INC. | $22.99 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $22.50 | 2019 | |
| Boston Scientific Corporation | $20.73 | 2019 | |
| Pfizer INC. | $19.57 | 2019 | |
| Avanir Pharmaceuticals, INC. | $17.25 | 2019 | |
| Emd Serono, INC. | $16.91 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Sabin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.